药物涂层气球在慢性全闭塞中 皮肤冠状动脉干预 冠状动脉干预
Daniel O'Callaghan1, J J Coughlan1, Rory Durand2
1Department of Cardiology, Cardiovascular Research Institute (CVRI), Mater Private Network, 73 Eccles Street, Dublin D07 KWR1, Ireland; RCSI School of Medicine and Health Sciences, Dublin, Ireland.
药物涂层气球 (DCB) 血管整形治疗慢性全闭症 (CTO) 穿皮冠状动脉干预 (PCI) 显示越来越多的临床兴趣. 这份审查指导了DCB与CTO PCI计划的整合,讨论了证据和现实世界的应用.
科学领域:
- 干预心脏病学 干预心脏病学
- 血管医学 血管医学
- 医疗器械 医疗器械
背景情况:
- 慢性全塞 (CTO) 穿皮冠状动脉干预 (PCI) 提出了独特的挑战.
- 药物涂层气球 (DCB) 血管整形正在成为复杂PCI的有希望的辅助.
- 在CTO PCI中优化DCB的使用需要了解当前的证据和实际实施.
研究的目的:
- 在CTO PCI中审查DCB血管造形术的原则.
- 总结DCB CTO PCI的现有临床证据和正在进行的试验.
- 为将DCB血管造形术纳入CTO PCI计划提供实际指导.
主要方法:
- 关于DCB CTO PCI原则和证据的文献审查.
- 分析当前的临床数据和正在进行的试验信息.
- 案例说明DCB CTO PCI程序和实用性的例子.
主要成果:
- DCB血管造形术是CTO PCI的一个发展战略.
- 临床证据和正在进行的试验正在扩大对CTO中DCB疗效的理解.
- 实践示例展示了DCB在现实世界CTO PCI中的潜在临床实用性.
结论:
- DCB血管整形具有显著的潜力,可以改善CTO PCI的结果.
- 进一步的研究和临床经验对于完善DCB CTO PCI技术至关重要.
- 将DCB整合到CTO PCI计划中可以增强复杂冠状动脉疾病的治疗选择.
相关概念视频
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Acute Coronary Syndrome IV: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...


